Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3704MR)

This product GTTS-WQ3704MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3704MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3693MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ3669MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ10754MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ2975MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ11372MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ5235MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ12885MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ2917MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW